GLP-1 Market
LLY $1213.13 ▲ +4.0% NVO $38.20 ▲ +0.4% PFE $29.39 ▲ +3.6% VKTX $25.86 ▼ -3.0% KLRA $10.88 ▲ +1.1% GPCR $22.28 ▼ -0.1% RHHBY $53.77 ▼ -0.6%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Test drug CB03-154 group

Test drug CB03-154 group

Company
Shanghai Zhimeng Biopharma, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 14, 2026

Find a Clinical Trial Near Me

See recruiting studies for Test drug CB03-154 group and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06612775

    A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy

    Not yet reported Shanghai Zhimeng Biopharma, Inc. 180 participants Est. completion 2027-11 1 site Stand-alone
    Other conditions: Focal Epilepsy
    View official trial listing →
  • Recruiting NCT NCT07082192

    A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

    Not yet reported, Not yet reported Shanghai Zhimeng Biopharma, Inc. 240 participants Est. completion 2027-10 1 site Stand-alone
    Other conditions: ALS (Amyotrophic Lateral Sclerosis)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Test drug CB03-154 group, Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 15mg group

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.